44 results about "Phenobarbital" patented technology

Methods and systems are provided for determining an increased likelihood of the occurrence of a cardiac arrhythmia, myocardial ischemia, congestive heart failure and other diseased conditions of the heart associated with elevated sympathetic neural discharges in a patient. The methods and systems comprise monitoring the sympathetic neural discharges of a patient from the stellate ganglia, the thoracic ganglia, or both, and detecting increases in the sympathetic neural discharges. The methods and systems may further comprise delivering therapy to the patient in response to a detected increase in the sympathetic neural discharge, such as delivering one or more pharmacological agents; stimulating myocardial hyperinnervation in the sinus node and right ventricle of the heart of the patient; and applying cardiac pacing, cardioversion or defibrillation shocks. Pharmacologic agents which may be used in connection with the delivery of include those which are known to exert anti-arrhythmic effect and anti-convulsant agents, such as phenytoin, carbamazepine, valproate, and phenobarbitone. Other pharmacologic agents may be used to treat impending myocardial ischemia and other diseased conditions of the heart associated with elevated sympathetic neural discharges.

Phenobarbital derivatives synthesized out of the alkyl chain at the 5-position, particularly with hydrophilic properties, and carrying an active ester at the end, allow formation of aminodextran conjugates that give curves in the desired range of the assay in the ONLINE TDM microparticle assay format when matched against the Roche FPIA antibody specific for phenobarbital (''an antibody specific for phenobarbital'').

The invention aims at providing a phenobarbital drug concentration testing device with the advantages of simpleness, convenience, quickness, high sensitivity and full automation and a preparation method thereof. In order to solve the abovementioned technical problems, the invention provides a phenobarbital homogeneous-phase enzyme immunoassay reagent kit and preparation method thereof, and the preparation method comprises synthesis of phenobarbital immunogens, preparation of anti-phenobarbital specific antibodies, preparation of enzyme-labeled conjugates and determination of a sample. The phenobarbital drug concentration homogeneous-phase enzyme immunoassay reagent kit provided by the invention has high accuracy and precision, the average recovery rate of serum specimens is larger than 95percent, and the related coefficient deviation is less than 2.5 percent. The specificity of phenobarbital antibodies provided in the reagent kit is strong; and during a test of drug-to-drug interactions, nearly no interaction among thirty tested common drugs and compounds occurs, and the phenobarbital drug concentration homogeneous-phase enzyme immunoassay reagent kit is suitable for clinically testing the concentration of the phenobarbital drug in the blood and has the advantages of simpleness, convenience, quickness, low cost, high sensitivity and full automation.

Methods and systems are provided for determining an increased likelihood of the occurrence of a cardiac arrhythmia, myocardial ischemia, congestive heart failure and other diseased conditions of the heart associated with elevated sympathetic neural discharges in a patient. The methods and systems comprise monitoring the sympathetic neural discharges of a patient from the stellate ganglia, the thoracic ganglia, or both, and detecting increases in the sympathetic neural discharges. The methods and systems may further comprise delivering therapy to the patient in response to a detected increase in the sympathetic neural discharge, such as delivering one or more pharmacological agents; stimulating myocardial hyperinnervation in the sinus node and right ventricle of the heart of the patient; and applying cardiac pacing, cardioversion or defibrillation shocks. Pharmacologic agents which may be used in connection with the delivery of include those which are known to exert anti-arrhythmic effect and anti-convulsant agents, such as phenytoin, carbamazepine, valproate, and phenobarbitone. Other pharmacologic agents may be used to treat impending myocardial ischemia and other diseased conditions of the heart associated with elevated sympathetic neural discharges.

The invention discloses a method for detecting residual tranquilizer medicines in a meat product. The method comprises the following steps: extracting and purifying by adopting a C18 solid phase extracting column, and then detecting by adopting a gas chromatography-mass spectrometer (GC-MS), so as to rapidly and exactly detect out the variety and the content of the residual tranquilizer medicines, including seven tranquilizer medicines, namely, diazepam, oxazepam, estazolam, alprazolam, triazolam, phenobarbital and promethazine, in the meat product. The method is suitable for detecting multiple tranquilizer medicine residues in complex substrate meat products such as sausage; the method has the advantages of being low in detection limit, accurate, fast, easy and convenient in operation and economic in detection cost, and can be developed and applied in detection mechanisms.

A method for determining blood-medicine concentration of antiepileptic medicine includes pre-treating sample to be determined and separating pretreated sample by acidic mobile phase in chromatographic column then utilizing ultraviolet detector to simultaneously detect quantitative concentration of phenobarbital, lamotrigine, oxcarbazepin and adipomono- oxcarbazepin as antiepileptic medicine.

Methods and systems are provided for determining an increased likelihood of the occurrence of a cardiac arrhythmia in a patient. The methods and systems comprise monitoring the sympathetic neural discharges of a patient from the left stellate ganglion, the thoracic ganglia, or both, and detecting increases in the sympathetic neural discharges. The methods and systems may further comprise delivering anti-arrhythmic therapy to the patient in response to a detected increase in the sympathetic neural discharge, such as delivering one or more pharmacological agents; stimulating myocardial hyperinnervation in the sinus node and right ventricle of the heart of the patient; and applying cardiac pacing, cardioversion or defibrillation shocks. Pharmacologic agents which may be used in connection with the delivery of anti-arrhythmic therapy include those which are known to exert anti-arrhythmic effect and anti-convulsant agents, such as phenyloin, carbamazepine, valproate, and phenobarbitone.

The present invention discloses a phenobarbital quick detection test paper strip. It contains bottom layer as supporting layer, intermediate layer as adsorption layer and protective layer fixed on the adsorption layer, Said adsorption layer successively includes test end adsorption fibre layer, adsorption gold-labelled amtibody fibre layer, cellulose membrane layer and water-absorbing material layer of handle end. Besides, said invention also provides the concrete structure on the cellulose membrane layer, said structure include linear detection blotting and linear reference blotting.

The invention discloses a compound immunoaffinity column for purifying phenobarbital and ractopamine as well as a preparation method and an application of the compound immunoaffinity column. 4% columnar agarose gel is adopted as a solid-phase carrier, the agarose gel is coupled with a phenobarbital antibody prepared with the method and a ractopamine antibody purchased in the market to form an immunoadsorbent, and the immunoadsorbent is put into a column to prepare the immunoaffinity column. When a sample containing phenobarbital and ractopamine passes through the immunoaffinity column, the immunoadsorbent specifically adsorbs phenobarbital and ractopamine, other impurities flow out of the immunoaffinity column, and then methanol is used to wash off phenobarbital and ractopamine from the column, so that the sample is well purified. The immunoaffinity column purification and liquid chromatography methods are created for detecting phenobarbital and ractopamine, so that the detection is quick, accurate and safe.

A medicine for treating toothache, dental marrow inflammation and periodontitis is prepared from VB1, VC, aminopyrine, phenacetin, coffeine, austrominal, prednisone acetate, and safflower.

The invention belongs to the field of pharmaceutic preparations, particularly relates to a phenobarbital oral cavity instant membrane and a preparation method thereof. The instant membrane comprises the following components in parts by weight: 5-10 parts of phenobarbital, 10-50 parts of a film-forming material, 1-10 parts of a plasticizer and 1-6 parts of a saliva irritant. According to the phenobarbital oral cavity instant membrane and the preparation method thereof, provided by the invention, due to the form of the membrane, drug administration can be carried out without water, the membrane can melt quickly in the oral cavity, that drugs are hidden in or spat out from the oral cavity of a patient is avoided, and the medication compliance of the patient is improved; besides, the main drugs of the instant membrane prepared by adopting the preparation method provided by the invention can be uniformly dispersed in a film-forming material, the finished product is good in appearance, the main drugs can quickly dissolve and is good in stability, the dosage of the product is accurate, dust flying in the production process is hardly caused, and the problem of labor protection and environmental pollution is solved.

The invention relates to a compound tetracaine composition as well as a preparation method and application thereof. The composition comprises the following raw medicines: tetracaine, ephedrine, phenobarbital, diphenhydramine, hydrocortisone and borneol. The compound tetracaine composition has the effects of removing necrotic tissue and promoting granulation, clearing heat and relieving pain, diminishing inflammation and resisting infection and promoting wound healing and has obvious curative effects of treating acute-stage anal fissure and acute attack of chronic anal fissure. When the compound tetracaine composition is matched with an anus suppository to perform non-surgical treatment of piles, the curative effects of the compound tetracaine composition on relieving bleeding, pain and abjection symptoms of piles are obvious. As a whole, the compound tetracaine composition has the advantages of obvious curative effect and the like, is quick to act, is convenient to use and is safe; and when the compound tetracaine composition is used, a patient does not feel pain; and effective rate reaches 100%.

The invention relates to oral phenobarbital freeze-dried powder and a preparation method thereof. The oral phenobarbital freeze-dried powder comprises phenobarbital and a freeze-dried skeleton agent. The oral phenobarbital freeze-dried powder prepared by adopting a freeze drying technology is quick in the solution rate and accurate in the dosage, and can be used for treating diseases like neonatal jaundice.

The invention discloses a medicine composition containing iodized lecithin and a preparation method thereof. The medicine composition containing iodized lecithin mainly comprises the following components: iodized lecithin, kaempferol, diosmin, stachydrine, blueberry anthocyanins, luteolin, chitin, puncturevine caltrop fruit saponins, phenobarbital, alpha-linolenic acid, taurine, riboflavin, nicotinic acid, amino acid, a filling agent, an adhesive, a disintegrating agent and a lubricating agent. The medicine composition has the beneficial effects that various effective components are combined through reasonable proportioning; the medicine composition achieves the functions of improving eyesight, eliminating ocular inflammation, increasing retina metabolism and regulating autoimmunity by improving ocular blood circulation, increasing corneal nutrition, resisting inflammation and oxidation and regulating the liver and kidneys, and has good prevention and treatment effects on cataract.

The invention belongs to the field of medicinal materials and carriers, and particularly discloses a phenobarbital sustained-release preparation which comprises a phenobarbital pharmaceutical active component, an excipient and a lubricant. The phenobarbital pharmaceutical active component accounts for 25-60% of the weight of the sustained-release preparation. The excipient is prepared from a gel skeleton material, a swelling material and a diluent, the gel skeleton material accounts for 10-50% of the weight of the sustained-release preparation, the swelling material accounts for 10-30% of theweight of the sustained-release preparation, and the diluent accounts for 0-15% of the weight of the sustained-release preparation. The gel skeleton material is composed of alginate and calcium salt,and the weight ratio of alginate to calcium salt is 2: 1 to 8: 1. The lubricant accounts for 0.7-2.5% of the weight of the sustained-release preparation. After the sustained release preparation disclosed by the invention is used, acid-insoluble gel with good strength is rapidly formed, so that the phenobarbital drug release speed is reduced, the drug can be released and absorbed for a longer time,and the bioavailability of the drug is improved.